New: our quarterly report on the S&P 500, read from 500 companies’ own filings and calls. Read the Q3 2026 report

Generate Biomedicines, Inc. (GENB) vs LB Pharmaceuticals Inc (LBRX)

Generate Biomedicines, Inc. and LB Pharmaceuticals Inc are both Biotechnology companies. Generate Biomedicines, Inc. and LB Pharmaceuticals Inc are of similar size ($1.3B and $1.3B). LB Pharmaceuticals Inc has the higher net margin (0.00% vs −1,326.8%) and the lower return on invested capital (−686.2% vs 0.00%). Across the 13 metrics below, LB Pharmaceuticals Inc leads on 10 and Generate Biomedicines, Inc. on 3.

Valuation

Metric GENB LBRX Biotechnology median
P/E n/m n/m 8.26
P/S 63.31 n/m 9.20
P/B 3.50 3.17 2.09
Price to free cash flow n/m n/m 24.49
EV/EBITDA n/m n/m 0.67
EV/Sales 44.41 n/m 9.05
Earnings yield (39.94%) (11.54%) (34.24%)
Free cash flow yield (18.94%) (10.86%) (24.77%)

Profitability

Metric GENB LBRX Biotechnology median
Gross margin 100.00% — 70.18%
Operating margin (1,382.04%) 0.00% 0.00%
Net margin (1,326.75%) 0.00% 0.00%
Free cash flow margin (1,199.36%) 0.00% 0.00%
Return on equity 1,047.66% (38.80%) (51.58%)
Return on assets (54.06%) (36.48%) (45.91%)
Return on invested capital 0.00% (686.18%) 0.00%

Growth

Metric GENB LBRX Biotechnology median
Revenue growth (TTM) — — 7.20%
EPS growth (last fiscal year) (13.66%) 98.22% 29.04%
Revenue growth, 5-year CAGR — — 9.48%
Net income growth, 5-year CAGR — — 0.00%

Health

Metric GENB LBRX Biotechnology median
Debt to equity 0.02 0.00 0.00
Current ratio 5.01 14.78 4.83
Net debt to EBITDA 0.97 9.90 1.01

Dividend

Metric GENB LBRX Biotechnology median
Dividend yield — — 0.40%
Payout ratio — — —

Size

Metric GENB LBRX Biotechnology median
Market cap 1.34b 1.30b 155.23m

Compare with another peer

Any metric, up to five companies and an Excel export Powerpack